	US 11,872,271 B2
	High-affinity anti-VEGF antibody KLHa505
Yasufumi Murakami, Chiba (JP); Shigeki Mukoubata, Chiba (JP); Hirotada Akiyama, Chiba (JP); and Koji Konomi, Nara (JP)
Assigned to ORDER-MADE MEDICAL RESEARCH INC., Tsukuba (JP); and SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed by ORDER-MADE MEDICAL RESEARCH INC., Tsukuba (JP); and SANTEN PHARMACEUTICAL CO., LTD., Osaka (JP)
Filed on Apr. 13, 2021, as Appl. No. 17/229,271.
Application 17/229,271 is a continuation of application No. 16/067,931, granted, now 11,007,259, previously published as PCT/JP2017/000101, filed on Jan. 5, 2017.
Claims priority of application No. 2016-001277 (JP), filed on Jan. 6, 2016.
Prior Publication US 2021/0228700 A1, Jul. 29, 2021
Int. Cl. A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01)

CPC A61K 39/001135 (2018.08) [A61P 35/00 (2018.01); C07K 16/22 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01)]

21 Claims

1. A monoclonal antibody against VEGF, or an antigen-binding fragment thereof, that binds to a vascular endothelial growth factor (VEGF), comprising:

CDR-H1 that comprises the amino acid sequence of SEQ ID NO: 14, CDR-H2 that comprises the amino acid sequence of SEQ ID NO: 16, and CDR-H3 that comprises the amino acid sequence of SEQ ID NO: 18; and CDR-L1 that comprises the amino acid sequence of SEQ ID NO: 20, CDR-L2 that comprises the amino acid sequence of Trp-Ala-Ser, and CDR-L3 that comprises the amino acid sequence of SEQ ID NO: 22.